688046 药康生物
午间休市 07-29 11:29:56
资讯
新帖
简况
7月28日药康生物跌6.10%，诺安先锋混合A基金重仓该股
证券之星 · 07-28 16:38
7月28日药康生物跌6.10%，诺安先锋混合A基金重仓该股
每周股票复盘：药康生物（688046）上半年净利预增46.67%至60.78%
证券之星 · 07-26
每周股票复盘：药康生物（688046）上半年净利预增46.67%至60.78%
信达生物全球首款口服周制剂小分子GLP-1申报临床；药康生物2026年上半年净利润预增46.67%至60.78%｜医药早参
每日经济新闻 · 07-23
信达生物全球首款口服周制剂小分子GLP-1申报临床；药康生物2026年上半年净利润预增46.67%至60.78%｜医药早参
药康生物与GCCL签署合作备忘录，共推全球药物发现与开发服务
美股速递 · 07-22
药康生物与GCCL签署合作备忘录，共推全球药物发现与开发服务
7月22日药康生物涨10.66%，诺安先锋混合A基金重仓该股
证券之星 · 07-22
7月22日药康生物涨10.66%，诺安先锋混合A基金重仓该股
股市必读：药康生物（688046）预计2026年1-6月扣非后净利润盈利9200万元至1亿元
证券之星 · 07-22
股市必读：药康生物（688046）预计2026年1-6月扣非后净利润盈利9200万元至1亿元
7月21日药康生物涨8.35%，诺安先锋混合A基金重仓该股
证券之星 · 07-21
7月21日药康生物涨8.35%，诺安先锋混合A基金重仓该股
药康生物(688046.SH)发预增，预计半年度归母净利润1.04亿元至1.14亿元，同比增长46.67%至60.78%
智通财经 · 07-21
药康生物(688046.SH)发预增，预计半年度归母净利润1.04亿元至1.14亿元，同比增长46.67%至60.78%
每周股票复盘：药康生物（688046）登龙虎榜因股价涨超15%
证券之星 · 07-19
每周股票复盘：药康生物（688046）登龙虎榜因股价涨超15%
7月17日药康生物跌20.00%，天弘医药创新A基金重仓该股
证券之星 · 07-17
7月17日药康生物跌20.00%，天弘医药创新A基金重仓该股
异动快报：药康生物（688046）7月15日10点35分触及涨停板
证券之星 · 07-15
异动快报：药康生物（688046）7月15日10点35分触及涨停板
7月1日药康生物涨6.49%，天弘医药创新A基金重仓该股
证券之星 · 07-01
7月1日药康生物涨6.49%，天弘医药创新A基金重仓该股
6月25日药康生物涨5.81%，天弘医药创新A基金重仓该股
证券之星 · 06-25
6月25日药康生物涨5.81%，天弘医药创新A基金重仓该股
每周股票复盘：药康生物（688046）拟每股派现0.19元
证券之星 · 06-07
每周股票复盘：药康生物（688046）拟每股派现0.19元
药康生物（688046）披露2025年年度权益分派实施公告，6月3日股价下跌1.15%
证券之星 · 06-03
药康生物（688046）披露2025年年度权益分派实施公告，6月3日股价下跌1.15%
药康生物（688046）披露2025年年度暨2026年第一季度业绩暨现金分红说明会公告，5月22日股价上涨0.34%
证券之星 · 05-22
药康生物（688046）披露2025年年度暨2026年第一季度业绩暨现金分红说明会公告，5月22日股价上涨0.34%
药康生物（688046）披露2025年度持续督导跟踪报告，5月19日股价下跌2.59%
证券之星 · 05-19
药康生物（688046）披露2025年度持续督导跟踪报告，5月19日股价下跌2.59%
每周股票复盘：药康生物（688046）调整激励计划行权价格
证券之星 · 05-17
每周股票复盘：药康生物（688046）调整激励计划行权价格
药康生物（688046）披露2022年限制性股票激励计划首次授予部分第三个归属期符合归属条件的公告，5月14日股价上涨1.52%
证券之星 · 05-14
药康生物（688046）披露2022年限制性股票激励计划首次授予部分第三个归属期符合归属条件的公告，5月14日股价上涨1.52%
药康生物（688046）披露保荐总结报告书，5月13日股价下跌2.11%
证券之星 · 05-13
药康生物（688046）披露保荐总结报告书，5月13日股价下跌2.11%
加载更多
公司概况
公司名称：
江苏集萃药康生物科技股份有限公司
所属行业：
研究和试验发展
上市日期：
2022-04-25
主营业务：
江苏集萃药康生物科技股份有限公司的主营业务是实验动物模型的研发创制、生产销售及相关技术服务。公司的主要产品是商品化小鼠模型、功能药效、定制繁育、模型创制、代理进出口及其他。
发行价格：
22.53
{"stockData":{"symbol":"688046","market":"SH","secType":"STK","nameCN":"药康生物","latestPrice":25.5,"timestamp":1785295796000,"preClose":25.69,"halted":0,"volume":6443320,"delay":0,"changeRate":-0.0074,"floatShares":409999999,"shares":409999999,"eps":0.3897,"marketStatus":"午间休市","change":-0.19,"latestTime":"07-29 11:29:56","open":25.72,"high":26.7,"low":24.64,"amount":165000000,"amplitude":0.0802,"askPrice":25.51,"askSize":4,"bidPrice":25.49,"bidSize":50,"shortable":0,"etf":0,"ttmEps":0.3897,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1785301200000},"marketStatusCode":3,"adr":0,"adjPreClose":25.69,"symbolType":"stock_kcb","openAndCloseTimeList":[[1785288600000,1785295800000],[1785301200000,1785308400000]],"highLimit":28.26,"lowLimit":23.12,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":410000000,"isCdr":false,"pbRate":4.62,"roa":"--","peRate":65.43495,"roe":"2.09%","epsLYR":0.35,"committee":0.378641,"marketValue":10455000000,"turnoverRate":0.0157,"status":1,"floatMarketCap":10455000000},"requestUrl":"/m/hq/s/688046","defaultTab":"news","newsList":[{"id":"2654907220","title":"7月28日药康生物跌6.10%，诺安先锋混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2654907220","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2654907220?lang=zh_cn&edition=full","pubTime":"2026-07-28 16:38","pubTimestamp":1785227923,"startTime":"0","endTime":"0","summary":"证券之星消息，7月28日药康生物跌6.10%，收盘报25.69元，换手率2.34%，成交量9.6万手，成交额2.52亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共25家，其中持有数量最多的公募基金为诺安基金的诺安先锋混合A。诺安先锋混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072800026402.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688046","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654503850","title":"每周股票复盘：药康生物（688046）上半年净利预增46.67%至60.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=2654503850","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2654503850?lang=zh_cn&edition=full","pubTime":"2026-07-26 03:20","pubTimestamp":1785007223,"startTime":"0","endTime":"0","summary":"截至2026年7月24日收盘，药康生物报收于26.2元，较上周的23.2元上涨12.93%。本周，药康生物7月22日盘中最高价报28.85元。本周关注点来自业绩披露要点：药康生物预计2026年上半年归母净利润同比增长46.67%至60.78%。公司公告汇总江苏集萃药康生物科技股份有限公司预计2026年半年度实现归属于母公司所有者的净利润10,400万元至11,400万元，同比增长46.67%至60.78%；扣除非经常性损益后的净利润为9,200万元至10,000万元，同比增长46.20%至58.92%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072600001126.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653791754","title":"信达生物全球首款口服周制剂小分子GLP-1申报临床；药康生物2026年上半年净利润预增46.67%至60.78%｜医药早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2653791754","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653791754?lang=zh_cn&edition=full","pubTime":"2026-07-23 07:02","pubTimestamp":1784761351,"startTime":"0","endTime":"0","summary":"｜2026年7月23日星期四｜NO.1信达生物：全球首款口服周制剂小分子GLP-1申报临床7月21日，信达生物IBI3042的临床试验申请获国家药监局受理。今年6月，公司已在美国糖尿病学会（ADA）年会上披露了包括IBI3042在内的多项代谢管线数据。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607233817817194.html","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607233817817194.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["GLP","JDOC","01801","159938","09939","688046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143060040","title":"药康生物与GCCL签署合作备忘录，共推全球药物发现与开发服务","url":"https://stock-news.laohu8.com/highlight/detail?id=1143060040","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1143060040?lang=zh_cn&edition=full","pubTime":"2026-07-22 22:14","pubTimestamp":1784729653,"startTime":"0","endTime":"0","summary":"药康生物与GCCL公司签署了一份谅解备忘录，旨在共同推进全球药物发现与开发服务。这一战略合作标志着双方在整合资源与专业技术方面迈出了关键一步，致力于为全球生物医药研发提供更高效、更创新的解决方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0216","688046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653753623","title":"7月22日药康生物涨10.66%，诺安先锋混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2653753623","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653753623?lang=zh_cn&edition=full","pubTime":"2026-07-22 16:42","pubTimestamp":1784709759,"startTime":"0","endTime":"0","summary":"证券之星消息，7月22日药康生物涨10.66%，收盘报27.0元，换手率5.47%，成交量22.44万手，成交额6.11亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共25家，其中持有数量最多的公募基金为诺安基金的诺安先锋混合A。诺安先锋混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072200034117.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653041162","title":"股市必读：药康生物（688046）预计2026年1-6月扣非后净利润盈利9200万元至1亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2653041162","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653041162?lang=zh_cn&edition=full","pubTime":"2026-07-22 01:03","pubTimestamp":1784653394,"startTime":"0","endTime":"0","summary":"截至2026年7月21日收盘，药康生物报收于24.4元，上涨8.35%，换手率4.6%，成交量18.87万手，成交额4.25亿元。业绩披露要点业绩预告预计2026年1-6月扣非后净利润盈利9200万元至1亿元；归属净利润盈利1.04亿元至1.14亿元。公司公告汇总药康生物2026年半年度业绩预告的自愿性披露公告预计2026年半年度实现归属于母公司所有者的净利润10,400万元至11,400万元，同比增长46.67%至60.78%；扣除非经常性损益后的净利润为9,200万元至10,000万元，同比增长46.20%至58.92%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072200001326.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653227073","title":"7月21日药康生物涨8.35%，诺安先锋混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2653227073","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653227073?lang=zh_cn&edition=full","pubTime":"2026-07-21 16:32","pubTimestamp":1784622770,"startTime":"0","endTime":"0","summary":"证券之星消息，7月21日药康生物涨8.35%，收盘报24.4元，换手率4.6%，成交量18.87万手，成交额4.25亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共8家，其中持有数量最多的公募基金为诺安基金的诺安先锋混合A。诺安先锋混合A目前规模为39.18亿元，最新净值3.5178，较上一交易日下跌1.9%，近一年上涨28.93%。诺安先锋混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072100030455.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688046","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653227560","title":"药康生物(688046.SH)发预增，预计半年度归母净利润1.04亿元至1.14亿元，同比增长46.67%至60.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=2653227560","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653227560?lang=zh_cn&edition=full","pubTime":"2026-07-21 16:06","pubTimestamp":1784621177,"startTime":"0","endTime":"0","summary":"智通财经APP讯，药康生物 发布2026年半年度业绩预告，公司预计2026年半年度实现归属于母公司所有者的净利润1.04亿元至1.14亿元，同比增加46.67%至60.78%。预计2026年半年度归属于母公司所有者的扣除非经常性损益的净利润9200万元至1亿元，同比增加46.20%至58.92%。报告期内，公司锚定国际化和创新的核心战略，一方面加快海外市场销售网络的布局和完善，另一方面持续加大研发资源投入，技术与产品的行业领先优势得到进一步巩固强化。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1470311.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"药康生物(688046.SH)发预增，预计半年度归母净利润1.04亿元至1.14亿元，同比增长46.67%至60.78%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652323772","title":"每周股票复盘：药康生物（688046）登龙虎榜因股价涨超15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2652323772","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652323772?lang=zh_cn&edition=full","pubTime":"2026-07-19 01:56","pubTimestamp":1784397372,"startTime":"0","endTime":"0","summary":"截至2026年7月17日收盘，药康生物报收于23.2元，较上周的25.46元下跌8.88%。本周，药康生物7月16日盘中最高价报31.0元，股价触及近一年最高点。7月14日盘中最低价报23.15元。药康生物当前最新总市值95.12亿元，在医疗服务板块市值排名20/51，在两市A股市值排名1784/5199。本周关注点来自交易信息汇总：药康生物因日收盘价格涨幅达15%登上龙虎榜。此次是近5个交易日内第1次上榜。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071900000470.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688046","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652055364","title":"7月17日药康生物跌20.00%，天弘医药创新A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2652055364","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652055364?lang=zh_cn&edition=full","pubTime":"2026-07-17 16:19","pubTimestamp":1784276379,"startTime":"0","endTime":"0","summary":"证券之星消息，7月17日药康生物跌20.00%，收盘报23.2元，换手率5.3%，成交量21.71万手，成交额5.32亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共5家，其中持有数量最多的公募基金为天弘基金的天弘医药创新A。天弘医药创新A目前规模为5.71亿元，最新净值1.1268，较上一交易日下跌0.63%，近一年上涨18.5%。天弘医药创新A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071700029649.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","BK1515","688046","BK1574","BK0216","09939","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651435503","title":"异动快报：药康生物（688046）7月15日10点35分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2651435503","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651435503?lang=zh_cn&edition=full","pubTime":"2026-07-15 10:45","pubTimestamp":1784083527,"startTime":"0","endTime":"0","summary":"证券之星7月15日盘中消息，10点35分药康生物（688046）触及涨停板。其所属行业医疗服务目前上涨。领涨股为药康生物。该股为基因编辑概念热股，当日基因编辑概念上涨4.88%。7月14日的资金流向数据方面，主力资金净流出716.65万元，占总成交额3.45%，游资资金净流出140.38万元，占总成交额0.68%，散户资金净流入857.03万元，占总成交额4.13%。近5日资金流向一览见下表：药康生物主要指标及行业内排名如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071500015840.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688046","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648515767","title":"7月1日药康生物涨6.49%，天弘医药创新A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2648515767","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648515767?lang=zh_cn&edition=full","pubTime":"2026-07-01 16:38","pubTimestamp":1782895086,"startTime":"0","endTime":"0","summary":"证券之星消息，7月1日药康生物涨6.49%创60日新高，收盘报25.77元，换手率2.65%，成交量10.88万手，成交额2.68亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共5家，其中持有数量最多的公募基金为天弘基金的天弘医药创新A。天弘医药创新A目前规模为5.71亿元，最新净值0.9745，较上一交易日下跌0.07%，近一年上涨10.94%。天弘医药创新A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070100031214.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09939","159938","BK1161","688046","BK1515","BK1574","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646873987","title":"6月25日药康生物涨5.81%，天弘医药创新A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2646873987","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646873987?lang=zh_cn&edition=full","pubTime":"2026-06-25 16:34","pubTimestamp":1782376492,"startTime":"0","endTime":"0","summary":"证券之星消息，6月25日药康生物涨5.81%创60日新高，收盘报22.41元，换手率2.68%，成交量10.98万手，成交额2.37亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共5家，其中持有数量最多的公募基金为天弘基金的天弘医药创新A。天弘医药创新A目前规模为5.71亿元，最新净值0.9176，较上一交易日上涨3.12%，近一年上涨6.98%。天弘医药创新A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062500029566.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09939","BK1574","BK1515","159938","BK0216","688046","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641212729","title":"每周股票复盘：药康生物（688046）拟每股派现0.19元","url":"https://stock-news.laohu8.com/highlight/detail?id=2641212729","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641212729?lang=zh_cn&edition=full","pubTime":"2026-06-07 02:55","pubTimestamp":1780772110,"startTime":"0","endTime":"0","summary":"截至2026年6月5日收盘，药康生物报收于17.63元，较上周的19.39元下跌9.08%。本周，药康生物6月1日盘中最高价报19.65元。本周关注点公司公告汇总：药康生物2025年年度权益分派拟每股派发现金红利0.19元（含税）。华泰联合证券有限责任公司关于江苏集萃药康生物科技股份有限公司差异化分红事项的核查意见华泰联合证券对江苏集萃药康生物科技股份有限公司2025年年度利润分配涉及的差异化分红事项进行了核查。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060700000938.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640790876","title":"药康生物（688046）披露2025年年度权益分派实施公告，6月3日股价下跌1.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2640790876","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640790876?lang=zh_cn&edition=full","pubTime":"2026-06-03 17:44","pubTimestamp":1780479864,"startTime":"0","endTime":"0","summary":"截至2026年6月3日收盘，药康生物报收于18.04元，较前一交易日下跌1.15%，最新总市值为73.96亿元。该股当日开盘18.3元，最高18.34元，最低17.87元，成交额达5552.32万元，换手率为0.75%。公司于近日披露《2025年年度权益分派实施公告》。股权登记日为2026年6月8日，除权（息）日和现金红利发放日均为2026年6月9日。公司回购专用账户股份不参与分红。差异化分红导致除权（息）参考价格按前收盘价减去0.190元计算。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060300036403.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688046","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637138348","title":"药康生物（688046）披露2025年年度暨2026年第一季度业绩暨现金分红说明会公告，5月22日股价上涨0.34%","url":"https://stock-news.laohu8.com/highlight/detail?id=2637138348","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637138348?lang=zh_cn&edition=full","pubTime":"2026-05-22 22:41","pubTimestamp":1779460873,"startTime":"0","endTime":"0","summary":"截至2026年5月22日收盘，药康生物报收于20.9元，较前一交易日上涨0.34%，最新总市值为85.69亿元。近日，江苏集萃药康生物科技股份有限公司发布《关于召开2025年年度暨2026年第一季度业绩暨现金分红说明会的公告》。公告显示，公司将于2026年6月1日10:00-11:00通过上证路演中心网络互动方式召开说明会，介绍公司2025年年度报告及2026年一季度报告的经营成果和财务状况。会后可通过上证路演中心查看会议情况。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052200045479.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688046","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636596857","title":"药康生物（688046）披露2025年度持续督导跟踪报告，5月19日股价下跌2.59%","url":"https://stock-news.laohu8.com/highlight/detail?id=2636596857","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636596857?lang=zh_cn&edition=full","pubTime":"2026-05-19 22:37","pubTimestamp":1779201433,"startTime":"0","endTime":"0","summary":"截至2026年5月19日收盘，药康生物报收于20.65元，较前一交易日下跌2.59%，最新总市值为84.66亿元。该股当日开盘21.01元，最高21.47元，最低20.35元，成交额达9127.91万元，换手率为1.08%。近日，华泰联合证券有限责任公司发布《关于江苏集萃药康生物科技股份有限公司2025年度持续督导跟踪报告》。2025年公司营收和净利润实现增长，研发投入占比略有下降，募集资金使用合规。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051900044129.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688046","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636064494","title":"每周股票复盘：药康生物（688046）调整激励计划行权价格","url":"https://stock-news.laohu8.com/highlight/detail?id=2636064494","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636064494?lang=zh_cn&edition=full","pubTime":"2026-05-17 03:35","pubTimestamp":1778960110,"startTime":"0","endTime":"0","summary":"截至2026年5月15日收盘，药康生物报收于21.51元，较上周的20.48元上涨5.03%。本周关注点公司公告汇总：药康生物调整2025年股票增值权激励计划行权价格至6.98元/股。药康生物于2026年5月12日召开第二届董事会第十八次会议，审议通过多项议案。药康生物于2026年5月14日召开2025年年度股东会，审议通过2025年年度报告、利润分配预案、续聘审计机构等议案，出席会议股东76人，代表表决权61.8279%，所有议案均获通过。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051700001097.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635716311","title":"药康生物（688046）披露2022年限制性股票激励计划首次授予部分第三个归属期符合归属条件的公告，5月14日股价上涨1.52%","url":"https://stock-news.laohu8.com/highlight/detail?id=2635716311","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635716311?lang=zh_cn&edition=full","pubTime":"2026-05-14 18:37","pubTimestamp":1778755032,"startTime":"0","endTime":"0","summary":"截至2026年5月14日收盘，药康生物报收于20.76元，较前一交易日上涨1.52%，最新总市值为85.12亿元。该股当日开盘20.44元，最高21.17元，最低20.35元，成交额达1.22亿元，换手率为1.43%。公告显示，公司2022年限制性股票激励计划首次授予部分第三个归属期归属条件已成就。本次拟归属限制性股票数量为24.44万股，归属人数为13人，股票来源为公司向激励对象定向发行A股普通股。归属价格为14.63元/股。激励对象个人绩效考核均达标，可归属比例为100%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051400035318.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688046","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635278865","title":"药康生物（688046）披露保荐总结报告书，5月13日股价下跌2.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2635278865","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635278865?lang=zh_cn&edition=full","pubTime":"2026-05-13 18:07","pubTimestamp":1778666831,"startTime":"0","endTime":"0","summary":"截至2026年5月13日收盘，药康生物报收于20.45元，较前一交易日下跌2.11%，最新总市值为83.84亿元。该股当日开盘20.58元，最高20.73元，最低20.12元，成交额达9308.98万元，换手率为1.11%。公司于近日披露《华泰联合证券有限责任公司关于江苏集萃药康生物科技股份有限公司首次公开发行股票并在科创板上市之保荐总结报告书》。截至2025年12月31日，募集资金尚未使用完毕，保荐机构将继续履行持续督导责任。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051300033715.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688046","BK0216"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1785298630550,"stockEarnings":[{"period":"1week","weight":0.0529},{"period":"1month","weight":0.1268},{"period":"3month","weight":0.2572},{"period":"6month","weight":0.4816},{"period":"1year","weight":0.6498},{"period":"ytd","weight":0.6909}],"compareEarnings":[{"period":"1week","weight":-0.0132},{"period":"1month","weight":-0.0531},{"period":"3month","weight":-0.0716},{"period":"6month","weight":-0.0829},{"period":"1year","weight":0.0599},{"period":"ytd","weight":-0.0392}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"江苏集萃药康生物科技股份有限公司","boardCode":"AI0073","boardName":"研究和试验发展","stockholders":"9140人(较上一季度增加20.09%)","perCapita":"44857股","listingDate":"2022-04-25","address":"江苏省南京市浦口区江北新区学府路12号","registeredCapital":"41000万元","survey":" 江苏集萃药康生物科技股份有限公司的主营业务是实验动物模型的研发创制、生产销售及相关技术服务。公司的主要产品是商品化小鼠模型、功能药效、定制繁育、模型创制、代理进出口及其他。","listedPrice":22.53},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"药康生物(688046)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供药康生物(688046)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"药康生物,688046,药康生物股票,药康生物股票老虎,药康生物股票老虎国际,药康生物行情,药康生物股票行情,药康生物股价,药康生物股市,药康生物股票价格,药康生物股票交易,药康生物股票购买,药康生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"药康生物(688046)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供药康生物(688046)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}